FDA approval could trigger a $27 million fee.
Meda acquired worldwide rights to BioDelivery Sciences’ (BDSI) cancer pain treatment, Onsolis, for $3 million. The milestone payment covering this therapy, for which FDA approval is anticipated in the second quarter, is $27 million.
Through its collaboration with BDSI, Meda already holds U.S., EU, Canadian, and Mexican rights to the therapy. Meda points out that the signing of this agreement grants it access to markets such as Russia, Japan, South East Asia, and Australia.
“With Onsolis, we strengthen our pain product portfolio on several important markets,” notes Anders Lönner, Meda’s CEO. “The product is unique, patented, and fills an important medical need.”
